Pfizer reports ELREXFIO trial success while Pfizer stock sits 2.14 percent below its high

Published on 10/28/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MagnetisMM-32 showed 68 percent progression-free survival at 18 months. Pfizer stock costs EUR 26.54 on October 28, 2026, 0.41 percent below Xetra close.

Trial evidence and market context

Pfizer reported a MagnetisMM-32 primary-endpoint success on October 27, 2026, with more than 75 percent of ELREXFIO patients free from progression or death.
Grade 3 or higher infections occurred in 27.5 percent of ELREXFIO patients versus 18.1 percent in the comparator group.
Pfizer stock trades at EUR 26.54 at 12:57 p.m. CET at Lang & Schwarz on October 28, 2026, 0.41 percent below the Xetra close of October 27, 2026.
Pfizer's third-quarter corporate performance event is scheduled for November 3, 2026.

Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) reported a positive primary-endpoint result from the Phase 3 MagnetisMM-32 trial on October 27, 2026. At Lang & Schwarz, Pfizer stock was trading at EUR 26.54 on October 28, 2026, at 12:57 p.m. CET, 0.41 percent below the Xetra close.

According to Pfizer, ELREXFIO met the progression-free-survival endpoint in adults with relapsed or refractory multiple myeloma after anti-CD38 therapy and lenalidomide. The company said the treatment reduced the risk of disease progression or death against three established treatment regimens.

Trial results add earlier-line evidence

More than 75 percent of patients receiving ELREXFIO had not experienced progression or death at the interim analysis. Estimated progression-free survival was 68 percent at 18 months, while median progression-free survival had not yet been reached.

The result strengthens Pfizer's development case for using its BCMA-directed bispecific antibody earlier in the treatment sequence. Overall-survival data remain immature, so the current release provides an interim efficacy signal rather than a completed assessment of the study's key secondary endpoint.

What does 68 percent PFS mean?

The efficacy result comes with a measurable safety tradeoff. Grade 3 or higher infections occurred in 27.5 percent of patients receiving ELREXFIO, compared with 18.1 percent in the investigator-choice group; Grade 5 infections were 0.8 percent and 1.6 percent, respectively.

Pfizer said it plans to submit the findings to global health authorities and present detailed data at a future medical meeting. The company is also continuing studies of ELREXFIO as monotherapy and in combination approaches.

November 3 sets the next date

Pfizer's investor-relations event page lists November 3, 2026, at 10:00 a.m. ET for its third-quarter corporate performance, according to Pfizer. That event will give investors a scheduled opportunity to compare the clinical pipeline update with the company's latest financial performance.

Pfizer stock stays near its yearly high

Pfizer's EUR 26.54 Lang & Schwarz price is 2.14 percent below its EUR 27.12 52-week high and 28.09 percent above its EUR 20.72 52-week low as of October 28, 2026. The reference price is 0.41 percent below the Xetra close of October 27, 2026, at EUR 26.65.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.